LOW-GRADE GLIOMA
Clinical trials for LOW-GRADE GLIOMA explained in plain language.
Never miss a new study
Get alerted when new LOW-GRADE GLIOMA trials appear
Sign up with your email to follow new studies for LOW-GRADE GLIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New proton beam therapy aims to shrink brain tumors with fewer side effects
Disease control OngoingThis study tests a precise type of radiation called proton therapy for people with low-grade or certain grade 3 brain tumors. The goal is to see if it can control tumor growth as well as standard radiation while causing fewer side effects by sparing healthy brain tissue. About 63…
Matched conditions: LOW-GRADE GLIOMA
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Apr 29, 2026 01:20 UTC
-
New drug combo targets recurrent brain tumors in kids
Disease control TerminatedThis early-stage trial is testing the safety and best dose of two drugs, trametinib and everolimus, given together to children and young adults whose gliomas (a type of brain tumor) have come back after previous treatment. The study aims to find the highest dose that is safe and …
Matched conditions: LOW-GRADE GLIOMA
Phase: PHASE1 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Apr 29, 2026 01:07 UTC
-
New pill may beat chemo for kids with NF1 brain tumors
Disease control OngoingThis study tests whether a targeted drug called selumetinib works as well as or better than standard chemotherapy (carboplatin/vincristine) for children and young adults (ages 2–21) with NF1-related low-grade gliomas. The goal is to control tumor growth and improve vision in thos…
Matched conditions: LOW-GRADE GLIOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 29, 2026 01:06 UTC
-
Immunotherapy drug shows promise for brain tumor control
Disease control OngoingThis phase 2 trial tests whether the immunotherapy drug nivolumab can stop or slow the growth of IDH-mutant gliomas, a type of brain tumor. The study includes 62 adults whose tumors have a high number of mutations (hypermutator phenotype) or not. Participants receive nivolumab in…
Matched conditions: LOW-GRADE GLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 28, 2026 13:11 UTC
-
New study measures drug levels in brain tumors before surgery
Knowledge-focused OngoingThis early-phase trial enrolls 16 adults with recurrent IDH-mutant gliomas who are scheduled for surgery. Participants take niraparib for one month before their operation so researchers can measure how much drug gets into the tumor and how it affects cancer cells. The goal is to …
Matched conditions: LOW-GRADE GLIOMA
Phase: EARLY_PHASE1 • Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Apr 29, 2026 01:06 UTC